Oncolix is a clinical-stage biotechnology company that is focused on cancer. The company is currently conducting a Phase I clinical trial for the indication of ovarian cancer. The drug, Prolanta, is a prolactin receptor antagonist. The mechanism of action is autophagocytosis or autophagy.